HDACs and HDAC inhibitors in urothelial carcinoma - Perspectives for an antineoplastic treatment

Current Medicinal Chemistry

Volumn 24, Issue 37, 2017, Pages 4151-4165

  Pinkerneil, Maria ^a   Hoffmann, Michele J ^a   Schulz, Wolfgang A ^a   Niegisch, Gunter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Class I HDACs; HDAC inhibitors; HDACSs; Targeted therapy; Urothelial carcinoma

Indexed keywords

4SC 202; APICIDIN; BELINOSTAT; BG 45; BUTYRIC ACID; DOCETAXEL; DOXORUBICIN; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; KBH A 42; MOCETINOSTAT; PEMBROLIZUMAB; RETINOIC ACID; RGFP 966; ROMIDEPSIN; ST 80; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 85029380980     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170207142740     Document Type: Review

References (111)

1. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. GLOBOCAN 2012 v1.0; Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 212. [cited 2016 August 24]; [Available from: http://globocan. iarc.fr/]
2. Kiemeney, L.A.; Witjes, J.A.; Verbeek, A.L.; Heijbroek, R.P.; Debruyne, F.M. Dutch South-East Cooperative Urological Group. The clinical epidemiology of superficial bladder cancer. Br. J. Cancer, 1993, 67(4), 806-812.
3. Niegisch, G.; Koch, A.; Knievel, J.; Schulz, W.A.; Albers, P. [Signal transduction in urothelial cancer: How exactly do we know the targets for targeted therapy?]. Urologe A, 2010, 49(11), 1401-1405.
4. Schulz, W.A. Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer, 2006, 119(7), 1513-1518.
5. Knowles, M.A.; Hurst, C.D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer, 2015, 15(1), 25-41.
6. Schulz, W. Epigenetics of Urothelial Carcinoma. In: Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment, and Prognosis; Verma, M., Ed.; Humana Press: New York, 2015.
7. Hautmann, R.E.; de Petriconi, R.C.; Pfeiffer, C.; Volkmer, B.G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol., 2012, 61(5), 1039-1047.
8. Gupta, S.; Mahipal, A. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Contr., 2013, 20(3), 200-210.
9. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014, 507(7492), 315-322.
10. Niegisch, G.; Retz, M.; Thalgott, M.; Balabanov, S.; Honecker, F.; Ohlmann, C.H.; Stockle, M.; Bogemann, M.; Vom Dorp, F.; Gschwend, J.; Hartmann, A.; Ohmann, C.; Albers, P. Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a german phase II trial (AUO Trial AB 35/09). Oncology, 2015, 89(2), 70-78.
11. Krege, S.; Rexer, H.; vom Dorp, F.; de Geeter, P.; Klotz, T.; Retz, M.; Heidenreich, A.; Kuhn, M.; Kamradt, J.; Feyerabend, S.; Wulfing, C.; Zastrow, S.; Albers, P.; Hakenberg, O.; Roigas, J.; Fenner, M.; Heinzer, H.; Schrader, M. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05). BJU Int., 2014, 113(3), 429-436.
12. Gallagher, D.J.; Milowsky, M.I.; Gerst, S.R.; Ishill, N.; Riches, J.; Regazzi, A.; Boyle, M.G.; Trout, A.; Flaherty, A.M.; Bajorin, D.F. Phase II study of sunitinib in patients with metastatic urothelial cancer. J. Clin. Oncol., 2010, 28(8), 1373-1379.
13. Oudard, S.; Culine, S.; Vano, Y.; Goldwasser, F.; Theodore, C.; Nguyen, T.; Voog, E.; Banu, E.; Vieillefond, A.; Priou, F.; Deplanque, G.; Gravis, G.; Ravaud, A.; Vannetzel, J.M.; Machiels, J.P.; Muracciole, X.; Pichon, M.F.; Bay, J.O.; Elaidi, R.; Teghom, C.; Radvanyi, F.; Beuzeboc, P. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur. J. Cancer, 2015, 51(1), 45-54.
14. Miller, K. A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an open-label study of gemcitabine plus cisplatin with or without concomitant or sequential gefitinib in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Urol. Int., 2015.
15. Milowsky, M.I.; Dittrich, C.; Duran, I.; Jagdev, S.; Millard, F.E.; Sweeney, C.J.; Bajorin, D.; Cerbone, L.; Quinn, D.I.; Stadler, W.M.; Rosenberg, J.E.; Lochheed, M.; Sen, P.; Squires, M.; Shi, M.; Sternberg, C.N. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur. J. Cancer, 2014, 50(18), 3145-3152.
16. Knievel, J.; Schulz, W.A.; Greife, A.; Hader, C.; Lubke, T.; Schmitz, I.; Albers, P.; Niegisch, G. Multiple mechanisms mediate resistance to sorafenib in urothelial cancer. Int. J. Mol. Sci., 2014, 15(11), 20500-20517.
17. Nawroth, R.; Stellwagen, F.; Schulz, W.A.; Stoehr, R.; Hartmann, A.; Krause, B.J.; Gschwend, J.E.; Retz, M. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One, 2011, 6(11), e25709.
18. Guo, G.; Sun, X.; Chen, C.; Wu, S.; Huang, P.; Li, Z.; Dean, M.; Huang, Y.; Jia, W.; Zhou, Q.; Tang, A.; Yang, Z.; Li, X.; Song, P.; Zhao, X.; Ye, R.; Zhang, S.; Lin, Z.; Qi, M.; Wan, S.; Xie, L.; Fan, F.; Nickerson, M.L.; Zou, X.; Hu, X.; Xing, L.; Lv, Z.; Mei, H.; Gao, S.; Liang, C.; Gao, Z.; Lu, J.; Yu, Y.; Liu, C.; Li, L.; Fang, X.; Jiang, Z.; Yang, J.; Li, C.; Zhao, X.; Chen, J.; Zhang, F.; Lai, Y.; Lin, Z.; Zhou, F.; Chen, H.; Chan, H.C.; Tsang, S.; Theodorescu, D.; Li, Y.; Zhang, X.; Wang, J.; Yang, H.; Gui, Y.; Wang, J.; Cai, Z. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet., 2013, 45(12), 1459-1463.
19. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett., 2009, 277(1), 8-21.
20. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5(9), 769-784.
21. Fischle, W.; Dequiedt, F.; Hendzel, M.J.; Guenther, M.G.; Lazar, M.A.; Voelter, W.; Verdin, E. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell, 2002, 9(1), 45-57.
22. Lahm, A.; Paolini, C.; Pallaoro, M.; Nardi, M.C.; Jones, P.; Neddermann, P.; Sambucini, S.; Bottomley, M.J.; Lo Surdo, P.; Carfi, A.; Koch, U.; De Francesco, R.; Steinkuhler, C.; Gallinari, P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. USA, 2007, 104(44), 17335-17340.
23. Martin, M.; Kettmann, R.; Dequiedt, F. Class IIa histone deacetylases: regulating the regulators. Oncogene, 2007, 26(37), 5450-5467.
24. Clocchiatti, A.; Di Giorgio, E.; Demarchi, F.; Brancolini, C. Beside the MEF2 axis: Unconventional functions of HDAC4. Cell. Signal., 2013, 25(1), 269-276.
25. Cernotta, N.; Clocchiatti, A.; Florean, C.; Brancolini, C. Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility. Mol. Biol. Cell, 2011, 22(2), 278-289.
26. Martin, M.; Kettmann, R.; Dequiedt, F. Class IIa histone deacetylases: conducting development and differentiation. Int. J. Dev. Biol., 2009, 53(2-3), 291-301.
27. Parra, M. Class IIa HDACs-new insights into their functions in physiology and pathology. FEBS J., 2015, 282(9), 1736-1744.
28. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 2009, 10(1), 32-42.
29. Raichur, S.; Teh, S.H.; Ohwaki, K.; Gaur, V.; Long, Y.C.; Hargreaves, M.; McGee, S.L.; Kusunoki, J. Histone deacetylase 5 regulates glucose uptake and insulin action in muscle cells. J. Mol. Endocrinol., 2012, 49(3), 203-211.
30. Cohen, T.J.; Choi, M.C.; Kapur, M.; Lira, V.A.; Yan, Z.; Yao, T.P. HDAC4 regulates muscle fiber type-specific gene expression programs. Mol. Cells, 2015, 38(4), 343-348.
31. Clocchiatti, A.; Florean, C.; Brancolini, C. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. J. Cell. Mol. Med., 2011, 15(9), 1833-1846.
32. Valenzuela-Fernandez, A.; Cabrero, J.R.; Serrador, J.M.; Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol., 2008, 18(6), 291-297.
33. Wang, Z.; Zang, C.; Cui, K.; Schones, D.E.; Barski, A.; Peng, W.; Zhao, K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell, 2009, 138(5), 1019-1031.
34. Yang, P.H.; Zhang, L.; Zhang, Y.J.; Zhang, J.; Xu, W.F. HDAC6: physiological function and its selective inhibitors for cancer treatment. Drug Discov. Ther., 2013, 7(6), 233-242.
35. Oehme, I.; Linke, J.P.; Bock, B.C.; Milde, T.; Lodrini, M.; Hartenstein, B.; Wiegand, I.; Eckert, C.; Roth, W.; Kool, M.; Kaden, S.; Grone, H.J.; Schulte, J.H.; Lindner, S.; Hamacher-Brady, A.; Brady, N.R.; Deubzer, H.E.; Witt, O. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc. Natl. Acad. Sci. USA, 2013, 110(28), E2592-E2601.
36. Chen, J.; Sahakian, E.; Powers, J.; Lienlaf, M.; Perez-Villarroel, P.; Knox, T.; Villagra, A. Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods Mol. Biol., 2016, 1436, 147-165.
37. Deubzer, H.E.; Schier, M.C.; Oehme, I.; Lodrini, M.; Haendler, B.; Sommer, A.; Witt, O. HDAC11 is a novel drug target in carcinomas. Int. J. Cancer, 2013, 132(9), 2200-2208.
38. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules, 2015, 20(3), 3898-3941.
39. Ozawa, A.; Tanji, N.; Kikugawa, T.; Sasaki, T.; Yanagihara, Y.; Miura, N.; Yokoyama, M. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int., 2010, 105(8), 1181-1186.
40. Ozdag, H.; Teschendorff, A.E.; Ahmed, A.A.; Hyland, S.J.; Blenkiron, C.; Bobrow, L.; Veerakumarasivam, A.; Burtt, G.; Subkhankulova, T.; Arends, M.J.; Collins, V.P.; Bowtell, D.; Kouzarides, T.; Brenton, J.D.; Caldas, C. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics, 2006, 7, 90.
41. Poyet, C.; Jentsch, B.; Hermanns, T.; Schweckendiek, D.; Seifert, H.H.; Schmidtpeter, M.; Sulser, T.; Moch, H.; Wild, P.J.; Kristiansen, G. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin. Pathol., 2014, 14(1), 10.
42. Junqueira-Neto, S. Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. Mol. Carcinog., 2013, 54(7), 523-531.
43. Niegisch, G.; Knievel, J.; Koch, A.; Hader, C.; Fischer, U.; Albers, P.; Schulz, W.A. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol. Oncol., 2013, 31(8), 1770-1779.
44. Lehmann, M.; Hoffmann, M.J.; Koch, A.; Ulrich, S.M.; Schulz, W.A.; Niegisch, G. Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. J. Exp. Clin. Cancer Res., 2014, 33, 59.
45. Pinkerneil, M.; Hoffmann, M.J.; Deenen, R.; Kohrer, K.; Arent, T.; Schulz, W.A.; Niegisch, G. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol. Cancer Ther., 2016, 15(2), 299-312.
46. Xu, X.S.; Wang, L.; Abrams, J.; Wang, G. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J. Hematol. Oncol., 2011, 4, 17.
47. Kim, M.S.; Pinto, S.M.; Getnet, D.; Nirujogi, R.S.; Manda, S.S.; Chaerkady, R.; Madugundu, A.K.; Kelkar, D.S.; Isserlin, R.; Jain, S.; Thomas, J.K.; Muthusamy, B.; Leal-Rojas, P.; Kumar, P.; Sahasrabuddhe, N.A.; Balakrishnan, L.; Advani, J.; George, B.; Renuse, S.; Selvan, L.D.; Patil, A.H.; Nanjappa, V.; Radhakrishnan, A.; Prasad, S.; Subbannayya, T.; Raju, R.; Kumar, M.; Sreenivasamurthy, S.K.; Marimuthu, A.; Sathe, G.J.; Chavan, S.; Datta, K.K.; Subbannayya, Y.; Sahu, A.; Yelamanchi, S.D.; Jayaram, S.; Rajagopalan, P.; Sharma, J.; Murthy, K.R.; Syed, N.; Goel, R.; Khan, A.A.; Ahmad, S.; Dey, G.; Mudgal, K.; Chatterjee, A.; Huang, T.C.; Zhong, J.; Wu, X.; Shaw, P.G.; Freed, D.; Zahari, M.S.; Mukherjee, K.K.; Shankar, S.; Mahadevan, A.; Lam, H.; Mitchell, C.J.; Shankar, S.K.; Satishchandra, P.; Schroeder, J.T.; Sirdeshmukh, R.; Maitra, A.; Leach, S.D.; Drake, C.G.; Halushka, M.K.; Prasad, T.S.; Hruban, R.H.; Kerr, C.L.; Bader, G.D.; Iacobuzio-Donahue, C.A.; Gowda, H.; Pandey, A. A draft map of the human proteome. Nature, 2014, 509(7502), 575-581.
48. Rosik, L.; Niegisch, G.; Fischer, U.; Jung, M.; Schulz, W.A.; Hoffmann, M.J. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol. Ther., 2014, 15(6), 742-757.
49. Lee, J.S.; Leem, S.H.; Lee, S.Y.; Kim, S.C.; Park, E.S.; Kim, S.B.; Kim, S.K.; Kim, Y.J.; Kim, W.J.; Chu, I.S. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol., 2010, 28(16), 2660-2667.
50. Schneider, B.J.; Kalemkerian, G.P.; Bradley, D.; Smith, D.C.; Egorin, M.J.; Daignault, S.; Dunn, R.; Hussain, M. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest. New Drugs, 2012, 30(1), 249-257.
51. Munster, P.N.; Marchion, D.; Thomas, S.; Egorin, M.; Minton, S.; Springett, G.; Lee, J.H.; Simon, G.; Chiappori, A.; Sullivan, D.; Daud, A. Phase I trial of vorinostat and doxorubicin in solid tumours: Histone deacetylase 2 expression as a predictive marker. Br. J. Cancer, 2009, 101(7), 1044-1050.
52. Pili, R.; Salumbides, B.; Zhao, M.; Altiok, S.; Qian, D.; Zwiebel, J.; Carducci, M.A.; Rudek, M.A. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br. J. Cancer, 2012, 106(1), 77-84.
53. Kim, J.; Akbani, R.; Creighton, C.J.; Lerner, S.P.; Weinstein, J.N.; Getz, G.; Kwiatkowski, D.J. Invasive bladder cancer: Genomic insights and therapeutic promise. Clin. Cancer Res., 2015, 21(20), 4514-4524.
54. Richon, V.M.; Sandhoff, T.W.; Rifkind, R.A.; Marks, P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA, 2000, 97(18), 10014-10019.
55. Glaser, K.B.; Staver, M.J.; Waring, J.F.; Stender, J.; Ulrich, R.G.; Davidsen, S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther., 2003, 2(2), 151-163.
56. Byler, T.K.; Leocadio, D.; Shapiro, O.; Bratslavsky, G.; Stodgell, C.J.; Wood, R.W.; Messing, E.M.; Reeder, J.E. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol., 2012, 12, 21.
57. Qu, W.; Kang, Y.D.; Zhou, M.S.; Fu, L.L.; Hua, Z.H.; Wang, L.M. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol. Oncol., 2010, 28(6), 648-654.
58. Li, G.C.; Zhang, X.; Pan, T.J.; Chen, Z.; Ye, Z.Q. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int. J. Urol., 2006, 13(5), 581-586.
59. Gould, J.J.; Kenney, P.A.; Rieger-Christ, K.M.; Silva Neto, B.; Wszolek, M.F.; LaVoie, A.; Holway, A.H.; Spurrier, B.; Austin, J.; Cammarata, B.K.; Canes, D.; Libertino, J.A.; Summerhayes, I.C. Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J. Urol., 2010, 183(6), 2395-2402.
60. Canes, D.; Chiang, G.J.; Billmeyer, B.R.; Austin, C.A.; Kosakowski, M.; Rieger-Christ, K.M.; Libertino, J.A.; Summerhayes, I.C. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int. J. Cancer, 2005, 113(5), 841-848.
61. Cao, Q.F.; Qian, S.B.; Wang, N.; Zhang, L.; Wang, W.M.; Shen, H.B. TRPM2 mediates histone deacetylase inhibitioninduced apoptosis in bladder cancer cells. Cancer Biother. Radiopharm., 2015, 30(2), 87-93.
62. Chen, C.L.; Sung, J.; Cohen, M.; Chowdhury, W.H.; Sachs, M.D.; Li, Y.; Lakshmanan, Y.; Yung, B.Y.; Lupold, S.E.; Rodriguez, R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J. Pharmacol. Exp. Ther., 2006, 319(2), 533-542.
63. Vallo, S.; Xi, W.; Hudak, L.; Juengel, E.; Tsaur, I.; Wiesner, C.; Haferkamp, A.; Blaheta, R.A. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs, 2011, 22(10), 1002-1009.
64. Buckley, M.T.; Yoon, J.; Yee, H.; Chiriboga, L.; Liebes, L.; Ara, G.; Qian, X.; Bajorin, D.F.; Sun, T.T.; Wu, X.R.; Osman, I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J. Transl. Med., 2007, 5, 49.
65. Kang, M.R.; Kang, J.S.; Yang, J.W.; Kim, B.G.; Kim, J.A.; Jo, Y.N.; Lee, K.; Lee, C.W.; Lee, K.H.; Yun, J.; Kim, H.M.; Han, G.; Kang, J.S.; Park, S.K. Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines. Oncol. Lett., 2012, 3(1), 113-118.
66. Pinkerneil, M.; Hoffmann, M.J.; Kohlhof, H.; Schulz, W.A.; Niegisch, G. Evaluation of the therapeutic potential of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial carcinoma cell lines. Target. Oncol., 2016, 11(6), 783-798.
67. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62(17), 4916-4921.
68. Leoni, F. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med., 2005, 11(1-12), 1-15.
69. Tatamiya, T. Isozyme-selective activity of the HDAC inhibitor MS-275. Cancer Res., 2004, 64(7)(Suppl.), 567.
70. Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P.T.; Trachy-Bourget, M.C.; Kalita, A.; Liu, J.; Lu, A.H.; Zhou, N.Z.; Robert, M.F.; Gillespie, J.; Wang, J.J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; Macleod, A.R.; Besterman, J.M.; Li, Z. MGCD0103, a novel isotypeselective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther., 2008, 7(4), 759-768.
71. Henning, S.W. Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor. Eur. J. Cancer Suppl., 2010, 8(7), 61.
72. Wells, C.E.; Bhaskara, S.; Stengel, K.R.; Zhao, Y.; Sirbu, B.; Chagot, B.; Cortez, D.; Khabele, D.; Chazin, W.J.; Cooper, A.; Jacques, V.; Rusche, J.; Eischen, C.M.; McGirt, L.Y.; Hiebert, S.W. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One, 2013, 8(7), e68915.
73. Malvaez, M.; McQuown, S.C.; Rogge, G.A.; Astarabadi, M.; Jacques, V.; Carreiro, S.; Rusche, J.R.; Wood, M.A. HDAC3-selective inhibitor enhances extinction of cocaineseeking behavior in a persistent manner. Proc. Natl. Acad. Sci. USA, 2013, 110(7), 2647-2652.
74. Minami, J.; Suzuki, R.; Mazitschek, R.; Gorgun, G.; Ghosh, B.; Cirstea, D.; Hu, Y.; Mimura, N.; Ohguchi, H.; Cottini, F.; Jakubikova, J.; Munshi, N.C.; Haggarty, S.J.; Richardson, P.G.; Hideshima, T.; Anderson, K.C. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia, 2014, 28(3), 680-689.
75. Krennhrubec, K.; Marshall, B.L.; Hedglin, M.; Verdin, E.; Ulrich, S.M. Design and evaluation of Linkerless hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(10), 2874-2878.
76. Kelly, R.D.; Cowley, S.M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem. Soc. Trans., 2013, 41(3), 741-749.
77. Wilting, R.H.; Yanover, E.; Heideman, M.R.; Jacobs, H.; Horner, J.; van der Torre, J.; DePinho, R.A.; Dannenberg, J.H. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J., 2010, 29(15), 2586-2597.
78. Jurkin, J.; Zupkovitz, G.; Lagger, S.; Grausenburger, R.; Hagelkruys, A.; Kenner, L.; Seiser, C. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle, 2011, 10(3), 406-412.
79. Kang, M.R.; Kang, J.S.; Han, S.B.; Kim, J.H.; Kim, D.M.; Lee, K.; Lee, C.W.; Lee, K.H.; Lee, C.H.; Han, G.; Kang, J.S.; Kim, H.M.; Park, S.K. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem. Pharmacol., 2009, 78(5), 486-494.
80. Florl, A.R.; Schulz, W.A. Chromosomal instability in bladder cancer. Arch. Toxicol., 2008, 82(3), 173-182.
81. Choudhary, S.; Wang, H.C. Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J. Cancer Res. Clin. Oncol., 2009, 135(11), 1601-1613.
82. Choudhary, S.; Wang, H.C. Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Mol. Cancer Ther., 2007, 6(3), 1099-1111.
83. Choudhary, S.; Rathore, K.; Wang, H.C. Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Rasexpressing human urinary bladder cancer J82 cells. J. Cancer Res. Clin. Oncol., 2011, 137(3), 471-480.
84. Li, Q.Q.; Hao, J.J.; Zhang, Z.; Hsu, I.; Liu, Y.; Tao, Z.; Lewi, K.; Metwalli, A.R.; Agarwal, P.K. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach. Int. J. Oncol., 2016, 48(6), 2591-2607.
85. Kim, K.H.; Kim, W.; Howard, T.P.; Vazquez, F.; Tsherniak, A.; Wu, J.N.; Wang, W.; Haswell, J.R.; Walensky, L.D.; Hahn, W.C.; Orkin, S.H.; Roberts, C.W. SWI/SNFmutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat. Med., 2015, 21(12), 1491-1496.
86. Oehme, I.; Deubzer, H.E.; Wegener, D.; Pickert, D.; Linke, J.P.; Hero, B.; Kopp-Schneider, A.; Westermann, F.; Ulrich, S.M.; von Deimling, A.; Fischer, M.; Witt, O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res., 2009, 15(1), 91-99.
87. Rettig, I.; Koeneke, E.; Trippel, F.; Mueller, W.C.; Burhenne, J.; Kopp-Schneider, A.; Fabian, J.; Schober, A.; Fernekorn, U.; von Deimling, A.; Denbzer, H.E.; Milde, I.; Witt, O.; Oehme, I. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis., 2015, 6, e1657.
88. Hsieh, T.H.; Hsu, C.Y.; Tsai, C.F.; Long, C.Y.; Chai, C.Y.; Hou, M.F.; Lee, J.N.; Wu, D.C.; Wang, S.C.; Tsai, E.M. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget, 2015, 6(1), 494-509.
89. Kang, Z.H.; Wang, C.Y.; Zhang, W.L.; Zhang, J.T.; Yuan, C.H.; Zhao, P.W.; Lin, Y.Y.; Hong, S.; Li, C.Y.; Wang, L. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One, 2014, 9(6), e98894.
90. Stark, M.; Hayward, N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using highdensity single-nucleotide polymorphism arrays. Cancer Res., 2007, 67(6), 2632-2642.
91. Cohen, A.L.; Piccolo, S.R.; Cheng, L.; Soldi, R.; Han, B.; Johnson, W.E.; Bild, A.H. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med. Genomics, 2013, 6, 35.
92. Raman, J.D.; Mongan, N.P.; Tickoo, S.K.; Boorjian, S.A.; Scherr, D.S.; Gudas, L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res., 2005, 11(24 Pt 1), 8570-8576.
93. Arisan, S.; Buyuktuncer, E.D.; Palavan-Unsal, N.; Caskurlu, T.; Cakir, O.O.; Ergenekon, E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol. Int., 2005, 75(3), 252-257.
94. Wang, H.; Albadine, R.; Magheli, A.; Guzzo, T.J.; Ball, M.W.; Hinz, S.; Schoenberg, M.P.; Netto, G.J.; Gonzalgo, M.L. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol. Oncol., 2012, 30(4), 428-433.
95. Marek, L.; Hamacher, A.; Hansen, F.K.; Kuna, K.; Gohlke, H.; Kassack, M.U.; Kurz, T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J. Med. Chem., 2013, 56(2), 427-436.
96. Zuo, Q.; Wu, W.; Li, X.; Zhao, L.; Chen, W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol. Rep., 2012, 27(3), 819-824.
97. Haakenson, J.; Wu, J.Y.; Xiang, S.; Williams, K.A.; Bai, W.; Zhang, X. HDAC6-Dependent Functions in Tumor Cells: Crossroad with the MAPK Pathways. Crit. Rev. Oncog., 2015, 20(1-2), 65-81.
98. Oehme, I.; Lodrini, M.; Brady, N.R.; Witt, O. Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas. Autophagy, 2013, 9(12), 2163-2165.
99. Yang, Y.; Huang, Y.; Wang, Z.; Wang, H.T.; Duan, B.; Ye, D.; Wang, C.; Jing, R.; Leng, Y.; Xi, J.; Chen, W.; Wang, G.; Jia, W.; Zhu, S.; Kang, J. HDAC10 promotes lung cancer proliferation via AKT phosphorylation. Oncotarget, 2016, 7(37), 59388-59401.
100. Jin, Z.; Jiang, W.; Jiao, F.; Guo, Z.; Hu, H.; Wang, L.; Wang, L. Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients. Int. J. Clin. Exp. Pathol., 2014, 7(9), 5872-5879.
101. Powers, J.; Lienlaf, M.; Perez-Villarroel, P.; Deng, S.; Knox, T.; Villagra, A.; Sahakian, E. Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods Mol. Biol., 2016, 1436, 129-145.
102. Lee, J.H.; Jeong, E.G.; Choi, M.C.; Kim, S.H.; Park, J.H.; Song, S.H.; Park, J.; Bang, Y.J.; Kim, T.Y. Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol. Cells, 2010, 30(2), 107-112.
103. Kotian, S.; Liyanarachchi, S.; Zelent, A.; Parvin, J.D. Histone deacetylases 9 and 10 are required for homologous recombination. J. Biol. Chem., 2011, 286(10), 7722-7726.
104. Li, Y.; Peng, L.; Seto, E. Histone deacetylase 10 regulates the cell cycle G2/M phase transition via a novel Let-7-HMGA2-cyclin A2 pathway. Mol. Cell. Biol., 2015, 35(20), 3547-3565.
105. Radhakrishnan, R.; Li, Y.; Xiang, S.; Yuan, F.; Yuan, Z.; Telles, E.; Fang, J.; Coppola, D.; Shibata, D.; Lane, W.S.; Zhang, Y.; Zhang, X.; Seto, E. Histone deacetylase 10 regulates DNA mismatch repair and may involve the deacetylation of MutS homolog 2. J. Biol. Chem., 2015, 290(37), 22795-22804.
106. Sahakian, E.; Powers, J.J.; Chen, J.; Deng, S.L.; Cheng, F.; Distler, A.; Woods, D.M.; Rock-Klotz, J.; Sodre, A.L.; Youn, J.I.; Woan, K.V.; Villagra, A.; Gabrilovich, D.; Sotomayor, E.M.; Pinilla-Ibarz, J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol. Immunol., 2015, 63(2), 579-585.
107. Lin, L.; Hou, J.; Ma, F.; Wang, P.; Liu, X.; Li, N.; Wang, J.; Wang, Q.; Cao, X. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J. Immunol., 2013, 191(7), 3896-3904.
108. Cheng, F.; Lienlaf, M.; Perez-Villarroel, P.; Wang, H.W.; Lee, C.; Woan, K.; Woods, D.; Knox, T.; Bergman, J.; Pinilla-Ibarz, J.; Kozikowski, A.; Seto, E.; Sotomayor, E.M.; Villagra, A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol. Immunol., 2014, 60(1), 44-53.
109. Villagra, A.; Cheng, F.; Wang, H.W.; Suarez, I.; Glozak, M.; Maurin, M.; Nguyen, D.; Wright, K.L.; Atadja, P.W.; Bhalla, K.; Pinilla-Ibarz, J.; Seto, E.; Sotomayor, E.M. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol., 2009, 10(1), 92-100.
110. Tian, Y.; Jin, J.; Wang, C.; Lv, W.; Li, X.; Che, X.; Gong, Y.; Li, Y.; Li, Q.; Hou, J.; Wang, P.G.; Shen, J. A submilligram-synthesis protocol for in vitro screening of HDAC11 inhibitors. Bioorg. Med. Chem. Lett., 2016, 26(10), 2434-2437.
111. Oronsky, B.; Oronsky, N.; Knox, S.; Fanger, G.; Scicinski, J. Episensitization: therapeutic tumor resensitization by epigenetic agents: A review and reassessment. Anticancer. Agents Med. Chem., 2014, 14(8), 1121-1127.